Hawthorn executes deal with university
MADISON — Hawthorn Pharmaceuticals Inc. has struck a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer.
Under the terms of the agreement, Madison-based Hawthorn will receive an exclusive worldwide license to develop and commercialize the antibody portfolio.
“We are excited to be working with the world=-class cancer scientists at University of Pittsburgh’s Cancer Institute who have devoted their entire careers to improving people’s lives through cancer discovery,” said Rob Lewis, chief scientific officer at Hawthorn.
“There are many strengths created by our relationship with the University of Pittsburgh that promotes the rapid development of these novel antibodies,” said Max Draughn, president and CEO of Hawthorn. “Our collaboration is a shared vision to ultimately extend and improve the lives of many children and adults who suffer with various cancers.”
To sign up for Mississippi Business Daily Updates, click here.
FOLLOW THE MBJ ON TWITTERMy Tweets
Twang & Tourism: The Country Music Trail
Top Posts & Pages
- QUIRKY? NO, JERKY — Whatever your craving, Beef Jerky Outlets likely has the flavor among 200+ choices
- Oxford’s FNC getting new headquarters
- Officials set hunting dates for birds; expands dove season by 20 days
- MARTIN WILLOUGHBY — State roots key to Edge Theory's Joe Stradinger
- ALAN TURNER — The ‘Internet of things’ is focus of Camgian's Gary Butler
- Cochran's attorneys argue for dismissal of McDaniel's lawsuit
- TECH 21 — Mississippi's most wanted in technology
- Federal charges dropped against Shumate after guilty plea
- Higher rates for Humana, lower for Magnolia ahead on health exchange